AstraZeneca has asked Health Canada to review a new long-acting antibody combination that could be used to prevent symptomatic COVID-19.
If approved, it would be the first antibody protection of its kind in Canada.
The company says its clinical trials showed the antibody treatment was well tolerated and reduced the risk of developing symptomatic COVID-19 by 77 per cent compared to a placebo.
Get weekly health news
AstraZeneca Canada says it could be a good option for vulnerable populations who aren’t able to develop a strong protective response from a vaccine.
- Ontario’s medical regulator proposing sweeping changes to prescribing safer supply
- Possible pneumonic plague case: What to know and how experts are responding
- Eby defends his plan to tax the rich as campaigns tackle health care crisis
- Health Canada warns of possible false positives in pregnancy test recall
The company says preliminary findings show the antibodies neutralize recent COVID-19 variants, including the Delta and Mu variants.
Health Canada has said all COVID-19 vaccine and drug submissions will be prioritized and reviewed on an expedited timeline.
Comments
Want to discuss? Please read our Commenting Policy first.